
Jeff Bezos' mom's death spotlights Lewy body dementia symptoms and risks
The Amazon founder announced Jacklyn Bezos' death on Instagram, remembering her as a young mother who "pounced on the job of loving me with ferocity."
"She always gave so much more than she ever asked for," he wrote in the caption.
Jackie Bezos was diagnosed with LBD in 2020, according to her son, who noted that she "battled with the same dignity and courage that's shaped every aspect of her life."
Jeff Bezos detailed that after a "long fight" with the neurological disorder, his mother passed away surrounded by "so many of us who loved her."
"We were all so lucky to be in her life," he said. "I hold her safe in my heart forever."
The National Institute on Aging (NIA) describes LBD as a "complex and challenging" progressive brain disorder.
Abnormal protein deposits called Lewy bodies affect chemicals in the brain, which can lead to problems with thinking, movement, behavior, mood and other functions.
Early LBD symptoms can include changes in mood, vision and body functions like heart rate and digestion, the NIA and Mayo Clinic have reported.
It can also cause sleep issues, such as disorders like insomnia and restless leg syndrome.
Cognitive symptoms of LBD can include changes in thinking abilities, drowsiness, attention issues and visual hallucinations, the above sources stated.
LBD patients may also experience changes in mood and behavior like depression, anxiety, agitation, delusions or paranoia.
These symptoms can often be confused with Alzheimer's disease.
Physical symptoms can include slowness, muscle rigidity or stiffness, shuffling while walking, tremors or shaking, balance problems, stooped posture, loss of coordination, smaller handwriting, reduced facial expression, difficulty swallowing and a weak voice, Cleveland Clinic listed.
Other miscellaneous symptoms may occur, such as blood pressure complications, difficulty regulating body temperature, fainting, frequent falls, constipation, urinary incontinence and poor sense of smell.
LBD mostly affects people over the age of 50 and slightly impacts men more than women. Those with a family history of LBD or Parkinson's disease are at a greater risk, according to Mayo Clinic.
The condition can occur alone or along with other brain disorders, as people with Lewy bodies in the brain can also have the "plaques and tangles" associated with Alzheimer's, the above source reports.
As LBD is a progressive disease, symptoms will begin slowly and worsen over time, spanning an average of five to seven years from diagnosis to death — although the disease span can range from two to 20 years.
People experiencing symptoms may visit a primary care doctor, who will most likely refer them to a neurologist for proper diagnosis, the NIA noted.
Geriatric psychiatrists, neuropsychologists and geriatricians may also be able to diagnose the condition through testing and brain imaging.
Although there is currently no cure for LBD, research is improving, according to the NIA, and some symptoms may respond to treatments.
"Advances in science may one day lead to better diagnosis, improved care and new treatments," the NIA website states.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
The sober-curious generation? This map shows where Gen Z is reshaping U.S. drinking habits.
Gen Z is the sober-curious generation. Between 2011 and 2023, the number of adults aged 18 to 24 who drank alcohol dropped by 8 percentage points, according to survey data from the Centers for Disease Control and Prevention. Consumption among 25- to 34-year-olds has also fallen 5 percentage points over the past decade, making young adults the driving force behind America's diminishing alcohol consumption. Gen Z is driving the shift away from drinking. Even young people who do drink do so less frequently than previous generations. Nearly two-thirds of 18- to 34-year-olds say one to two drinks a day is bad for their health, reflecting changing attitudes toward drinking. These days, drinking less doesn't mean sacrificing a social life, though. Bars and liquor stores are catering to a growing demand for mocktails and zero-proof alcohol. Data from Eventbrite shows a 92% rise in sober-curious events across the country over the past year. These include everything from morning dance parties (20% rise) to DJ'd events with coffee instead of alcohol (478% rise). Advertisement Yahoo used data from Behavioral Risk Factor Surveillance System to examine the evolving drinking culture among young adults in the U.S. The map data is based on surveys conducted between 2011-2012 and 2022-2023.
Yahoo
4 minutes ago
- Yahoo
CVS unit must pay $290 million in drug whistleblower lawsuit, judge rules
A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it overcharged Medicare for prescription drugs. In a Tuesday decision, Chief Judge Mitchell Goldberg in Philadelphia federal court tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the federal False Claims Act. He added a $4.87 million civil fine. Goldberg rejected CVS' request to pay less, saying that while CVS Caremark was liable for only two years of overbilling, evidence at trial "made clear that the fraud was financially motivated, not the result of some innocent or mistaken belief." CVS, based in Woonsocket, said on Wednesday it plans to appeal. Last month, a Manhattan federal judge ordered CVS' Omnicare unit to pay $948.8 million in a separate whistleblower lawsuit alleging fraudulent billing. CVS plans to appeal that judgment. Goldberg presided in March over a non-jury trial in the whistleblower case brought by Sarah Behnke, a former head actuary for Medicare Part D at Aetna. She accused CVS Caremark of having caused health insurers such as Aetna to submit inflated claims since 2010 to the Centers for Medicare and Medicaid Services (CMS), while pharmacies such as Rite Aid and Walgreens WBA.O were paid less. CVS argued that the original $95 million in damages was substantial, and punitive damages should be limited to $95 million. But the judge said CVS Caremark's fraud not only financially harmed the government, but diminished public confidence in it. "CMS relies on companies like Caremark to truthfully and accurately report Part D drug prices," he wrote. "Caremark's conduct broke CMS's trust, and as a result, the public's trust in CMS." Behnke sued in 2014. CVS bought Aetna four years later. The False Claims Act lets whistleblowers sue on behalf of the government and share in recoveries, typically 15% to 30%. This article originally appeared on The Providence Journal: Judge: CVS Caremark overcharged Medicare for prescription drugs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
6 minutes ago
- Medscape
High Adherence to Dupilumab in Chronic Rhinosinusitis
TOPLINE: An analysis of a real-world US practice revealed that a substantial proportion of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who initiated dupilumab remained adherent at 12 months. Among those who discontinued therapy, over 40% resumed treatment within a short timeframe. METHODOLOGY: Researchers used real-world administrative claims and clinical data to analyze treatment patterns of 3318 patients (mean age, 47.1 years; 54.4% men) with CRSwNP who initiated dupilumab between June 2019 and December 2021. Persistence with dupilumab was defined as the interval from treatment initiation to either the end of a 60-day gap without a refill or a switch to another CRSwNP biologic (omalizumab or mepolizumab). Patients were considered adherent to dupilumab if they had a medication possession ratio ≥ 0.8 during the 12-month follow-up period. TAKEAWAY: Persistence rates among patients on dupilumab were 84.9% and 69.5% at 6 and 12 months, respectively, with an average follow-up duration of 375.6 days. Of 913 patients who discontinued dupilumab, 366 reinitiated the treatment after a median of 1.2 months, with reinitiation probabilities of 35.5% and 43.3% at 6 and 12 months, respectively. Treatment adherence was 75.2%, with a high mean medication possession ratio of 1.06. IN PRACTICE: 'Future studies examining discontinuation reasons and persistence patterns across type 2 comorbidity and AERD [aspirin-exacerbated respiratory disease] subgroups would enhance our understanding of dupilumab use in CRSwNP patients,' the authors of the study wrote. SOURCE: Zhixiao Wang, PhD, with Regeneron Pharmaceuticals, Inc., Tarrytown, New York, was the corresponding author of the study, which was published online on August 15 in The Journal of Allergy and Clinical Immunology: Global. LIMITATIONS: Reasons for dupilumab discontinuation could not be determined, dispensing for comorbid asthma or atopic dermatitis was not captured, and the 1-year continuous enrollment requirement may have introduced selection bias. In addition, the study findings may not be generalizable to other publicly insured or uninsured patients, and reliance on a subjective gap definition in claims data may have resulted in imprecise records of discontinuation timing. DISCLOSURES: The study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Three authors reported being employees of Regeneron Pharmaceuticals, Inc., and two reported being employees of Sanofi; all five may hold stock or stock options in their respective companies. Three additional authors reported being employees of Analysis Group. One author reported serving on the advisory board and speakers bureau for both Sanofi and Regeneron Pharmaceuticals, Inc. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.